Paramita Therapeutics, Inc. (Paramita) has been awarded a National Science Foundation Small Business Innovation Research grant for $255,990 to conduct research and development work on a novel dual-function therapeutic/vaccine product, designated as TheraVax™. TheraVax not only can block entry of SARS-CoV-2 but also can activate the immune system to produce effector T cells and neutralizing antibodies to eliminate SARS-CoV-2. This unique dual-function therapeutic/vaccine could work at an early stage of infection to prevent hospitalization and in mild or severe disease to block viral spread while activating appropriate immune responses.
November 19, 2025. https://www.einpresswire.com/article/868076000/paramita-therapeutics-inc-awarded-competitive-sbir-phase-1-grant-from-the-national-cancer-institute
Paramita Therapeutics, Inc. (Paramita) today announced that it has received a $353,009, one-year Small Business Innovation Research (SBIR) Phase 1 grant from the National Cancer Institute (NCI) of the National Institutes of Health under Award Number R43CA306207. The grant will fund the development of novel prostate-specific membrane antigen (PSMA)-targeted multivalent drug conjugates (MDCs) for advanced prostate cancer.